# Latigo Biotherapeutics’ Q3 Loss Per Share Beats Estimate by $0.12

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/50745
Published: 2026-11-07T10:18:39.000Z
Updated: 2026-11-07T10:18:39.000Z
Section: Business

> The company expects $401 million in cash and cash equivalents to fund operations into 2029.

Latigo Biotherapeutics, Inc. (LTGO) posted a third-quarter GAAP loss of $0.55 per share, beating estimates by $0.12. The company expects its $401 million in cash and cash equivalents to fund operations into 2029.